- 01Sabra rollout now covers 23 US communities and 808 memory-care licences.
- 02PainChek targets activation by 31 Dec; revenue depends on deployment.
PainChek Limited (ASX: PCK) has expanded its commercial agreements with Sabra Health Care from two facilities to 23 communities across five operators in the US, securing 808 contracted memory care licences.
Following an April master services agreement with the Nasdaq-listed healthcare property owner, the expansion marks a broader conversion of operator introductions into community-level contracts.
PainChek is now targeting implementation, staff training, and licence activation at all 23 communities by 31 December to translate those contracts into annual recurring revenue.
Its new leadership team has prioritised assisted living and memory care, estimating a potential market of 1.2 million licences worth A$100 million, although those figures are neither contracted demand nor revenue guidance.
Five Operators Involved
The 23 contracted communities comprise seven operated by The Claiborne, six by HDG, four each by AgeWell and Phoenix Senior Living, and two by Traditions Senior Living.
Those operators collectively manage 192 communities across their wider portfolios, creating a potential route to further contracts beyond the current Sabra sites, although additional deployment is not assured and will require further operator engagement and commercial agreements.
PainChek has initially focused on about 2,500 memory care licences within the wider Sabra deployment opportunity of up to 20,000 licences.
Sabra has helped reduce contractual and cost barriers for participating operators and continues to introduce PainChek across its senior housing portfolio.
Near-Term Priorities
The company intends to embed its AI-assisted pain assessment technology into established care workflows as communities move from signed agreements to active use.
Its commercial approach draws on existing integrations, operator relationships, and implementation experience in comparable residential care settings in both Australia and the United Kingdom.
“Assisted living and memory care provide an accessible US revenue opportunity where we have existing relationships, integrations, and implementation experience,” chief executive officer Karen Holzberger said.
“The Sabra relationship supports operator engagement and community-level adoption, and our immediate priority is to convert contracted uptake into recurring revenue.”
PainChek is seeking to build recurring income through initial deployments that can demonstrate clinical utility and encourage operators to extend use across more facilities.
Further Sales Channels
Outside the Sabra arrangement, a paid pilot with Silverado covers 203 licences at two sites, the first of which went live at the end of September.
Silverado operates 31 sites, representing a further estimated opportunity of 2,500 licences, but any rollout beyond the pilot depends on its evaluation and new customer agreements.
PainChek is also progressing conversations with other US assisted living and memory care operators while maintaining longer-term business development in skilled nursing, hospitals and home care.
Expansion into those additional settings will depend on integration readiness, clinical practices and applicable reimbursement and regulatory requirements.
At 30 June, PainChek had 90,198 implemented licences across 1,990 active sites, with implemented ARR of A$4.46m and 21.38 million cumulative pain assessments.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.